摘要
Hepsin是一种在细胞生长发育中发挥关键作用的II型跨膜丝氨酸蛋白酶(TTSP)。 Hepin在前列腺癌(PCa)中高度表达,与其进展和转移相关。因此,它被认为是PCa的有吸引力的生物标志物。近来,已经开发了针对hepsin的低分子量抑制剂。基于关键的化学支架,它们可以分为四类:吲哚甲酰胺,苯甲酰胺,基于肽的类似物和2,3-二氢-1H-伴侣二胺。在这次审查中,我们讨论了四种类型的蛋白酶抑制剂的设计策略,结构 - 活性关系(SAR)和结合模式
关键词: Hepsin,前列腺癌,II型跨膜丝氨酸蛋白酶,结构活性关系(SAR),脒,肽。
Current Medicinal Chemistry
Title:Recent Advances of Hepsin-Targeted Inhibitors
Volume: 24 Issue: 21
关键词: Hepsin,前列腺癌,II型跨膜丝氨酸蛋白酶,结构活性关系(SAR),脒,肽。
摘要: Hepsin is a type II transmembrane serine protease (TTSP) that plays a crucial role in cell growth and development. Hepsin is highly expressed in prostate cancer (PCa) and associated with its progression and metastasis. Therefore, it has been considered as an attractive biomarker of PCa. Recently, low molecular weight inhibitors targeting hepsin have been developed. Based on the key chemical scaffold, they can be classified into four classes: Indolecarboxamidines, benzamidines, peptide-based analogs, and 2,3-dihydro- 1H-perimidines. In this review, we discuss design strategy, structure-activity relationship (SAR), and binding mode of the four classes of hepsin inhibitors.
Export Options
About this article
Cite this article as:
Recent Advances of Hepsin-Targeted Inhibitors, Current Medicinal Chemistry 2017; 24 (21) . https://dx.doi.org/10.2174/0929867324666170227115835
DOI https://dx.doi.org/10.2174/0929867324666170227115835 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Smart Polymer Based Delivery Systems for Peptides and Proteins
Recent Patents on Drug Delivery & Formulation Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets The Utility of Proteomic Patterns for the Diagnosis of Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial [Hot Topic: GHRH Analogs and Cancer (Guest Editor: Hippokratis Kiaris )]
Combinatorial Chemistry & High Throughput Screening Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Near-Infrared Quantum Dots as Optical Probes for Tumor Imaging
Current Topics in Medicinal Chemistry Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Biomarkers Recent Advances in Registration Methods for MRI-TRUS Fusion Image-Guided Interventions of Prostate
Recent Patents on Engineering Selective Neuronal Nitric Oxide Synthase Inhibitors
Current Topics in Medicinal Chemistry MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters The Epigenomic Viewpoint on Cellular Differentiation of Myeloid Progenitor Cells as it Pertains to Leukemogenesis
Current Genomics